Syndax To Present At Two Upcoming Scientific Conferences
WALTHAM, Mass., Sept. 16, 2015 /PRNewswire/ -- Syndax Pharmaceuticals, Inc., a clinical stage biopharmaceutical company focused on developing entinostat as a combination therapy in multiple cancer indications, announced today that the Company's Chief Technology Officer, Peter Ordentlich, Ph.D., will be presenting at two upcoming scientific conferences: CRI-CIMT-EATI-AACR - The Inaugural International Cancer Immunotherapy Conference: Translating Science into Survival taking place September 16th to 19th in New York City, and at the 13th Annual Discovery on Target Conference taking place September 21st to 24th in Boston.
On Wednesday, September 16th from 6:45 p.m. to 8:45 p.m. ET, Dr. Ordentlich will be presenting Poster A030: Epigenetic immune modulation by entinostat in breast cancer: Correlative analysis of ENCORE 301 trial during Poster Session A: Clinical Trials of Cancer Immunotherapies. The poster summarizes findings from analyses of immune cell subsets from patients treated in Syndax's completed ENCORE 301 clinical trial.
On Monday, September 21st at 11:10 a.m. ET during a Symposium entitled "Next Generation Histone Deacetylase Inhibitors, Promising New Chemistries and Biological Strategies for Targeting HDACs," Dr. Ordentlich will present: Targeting Immunologic and Epigenetic Resistance in Solid Tumors Using HDAC1 Selective Inhibitor Entinostat, an update of recent scientific advances underlying the entinostat clinical development strategy.
About Syndax Pharmaceuticals, Inc.
Syndax is a clinical stage biopharmaceutical company developing entinostat as a combination therapy in multiple cancer indications with an initial focus on tumors that have shown sensitivity to immunotherapy, including lung cancer, melanoma and triple-negative breast cancer (TNBC). Entinostat is an oral, small molecule drug candidate that has direct effects on both cancer cells and immune regulatory cells, potentially enhancing the body's immune response to tumors. Entinostat is being evaluated as a combination therapeutic in Phase 1b/2 clinical trials with Merck & Co., Inc. for non-small cell lung cancer and melanoma and with Genentech, Inc. for TNBC, as well as a Phase 3 clinical trial with ECOG-ACRIN for advanced hormone receptor positive breast cancer. For more information on Syndax please visit www.syndax.com.
Investor and Media Contacts
Karen L. Bergman
BCC Partners
(650) 575-1509
[email protected]
Jen LaVin
BCC Partners
(617) 718-0276
[email protected]
SOURCE Syndax Pharmaceuticals, Inc.
Share this article